• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

In Utero Exposure to Certain Antiepileptics Tied to Neurodevelopmental Diagnoses

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 25, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Nov. 25, 2024 -- Exposure to certain antiseizure medications (ASMs) in utero is associated with an increased likelihood of neurodevelopmental diagnoses, according to a study published online Nov. 15 in Nature Communications.

Paul Madley-Dowd, Ph.D., from the University of Bristol in the United Kingdom, and colleagues created a cohort of 3,182,773 children, of whom 17,495 were exposed to ASMs in pregnancy, using routinely collected primary care data from the United Kingdom and nationwide Swedish registers to examine the long-term safety of ASMs.

The researchers found that compared with children not exposed to ASMs, those exposed to valproate were more likely to receive a diagnosis of autism, intellectual disability, and attention-deficit/hyperactivity disorder. Children exposed to topiramate were 2.5 times more likely to be diagnosed with intellectual disability, while those exposed to carbamazepine were 1.25 and 1.30 times more likely to be diagnosed with autism and intellectual disability, respectively. Little evidence was found to indicate that exposure to lamotrigine in pregnancy was associated with increased odds of neurodevelopmental diagnoses.

"The findings of this large-scale study suggest that topiramate, carbamazepine, and valproate, but not lamotrigine, use during pregnancy are associated with higher risks of neurodevelopmental conditions in exposed children," the authors write. "These observational associations translate to tangible absolute risk increases (ranging from 0.3 to 2.1 extra cases by age 12 per 100 children exposed in utero)."

One author disclosed ties to the pharmaceutical industry; a second author disclosed ties to law firms and AlphaSights.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted November 2024

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.